Advisor Partners LLC Purchases 65 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Advisor Partners LLC increased its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 8.6% in the 3rd quarter, HoldingsChannel reports. The fund owned 824 shares of the biopharmaceutical company’s stock after acquiring an additional 65 shares during the period. Advisor Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $229,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Accurate Investment Solutions Inc. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $31,000. HM Payson & Co. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $31,000. Coastal Capital Group Inc. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $38,000. Focused Wealth Management Inc increased its stake in Regeneron Pharmaceuticals by 1,333.3% during the 2nd quarter. Focused Wealth Management Inc now owns 129 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 120 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. increased its stake in Regeneron Pharmaceuticals by 104.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 143 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 73 shares in the last quarter. Hedge funds and other institutional investors own 66.55% of the company’s stock.

In related news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. Corporate insiders own 11.84% of the company’s stock.

A number of brokerages have issued reports on REGN. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, October 10th. Canaccord Genuity cut their price target on shares of Regeneron Pharmaceuticals from $353.00 to $320.00 and set a “hold” rating on the stock in a research note on Wednesday, October 9th. Guggenheim raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the company from $355.00 to $403.00 in a report on Monday, September 23rd. ValuEngine raised shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, October 17th. Finally, Credit Suisse Group dropped their price objective on shares of Regeneron Pharmaceuticals from $333.00 to $325.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average price target of $390.47.

REGN stock opened at $301.31 on Wednesday. The firm’s fifty day simple moving average is $289.03 and its 200-day simple moving average is $309.91. The company has a market capitalization of $33.56 billion, a P/E ratio of 15.22, a price-to-earnings-growth ratio of 1.32 and a beta of 1.14. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.88 and a quick ratio of 3.11. Regeneron Pharmaceuticals Inc has a 12 month low of $271.37 and a 12 month high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.60 by $0.69. The business had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.80 billion. Regeneron Pharmaceuticals had a net margin of 28.59% and a return on equity of 25.79%. The business’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same period in the prior year, the firm earned $5.45 EPS. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals Inc will post 18.91 earnings per share for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: How to trade on quiet period expirations

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit